Literature DB >> 11077218

Gene therapy of transplant arteriopathy by liposome-mediated transfection of endothelial nitric oxide synthase.

A Iwata1, S Sai, M Moore, J Nyhuis, R de Fries-Hallstrand, G C Quetingco, M D Allen.   

Abstract

BACKGROUND: Transplant arteriopathy is the major factor limiting long-term survival after cardiac transplantation. We have previously demonstrated that liposome-mediated gene delivery of endothelial nitric oxide synthase (eNOS) to donor hearts reduces ischemia-reperfusion injury by blocking NFkappaB activation, adhesion molecule expression, and leukocyte infiltration. In this study, we used gene transfer of eNOS in a rabbit carotid transplant model to see whether these same effects would similarly ameliorate transplant arteriopathy.
METHODS: Liposomes complexed to the gene encoding eNOS were injected into donor carotid arterial segments that were transplanted orthotopically into recipient carotid arteries (n = 10). Controls included transplanted carotids transfected with liposomes complexed to empty plasmids (no functional gene) (n = 4) and transplanted carotids treated with saline (n = 6). Transplanted arteries were harvested for processing at 21 days. Intima/media (I/M) area ratios were calculated by computerized image analysis. Infiltrating T-lymphocytes and macrophages, and expression of VCAM-1 and ICAM-1 were quantified on immunocytochemistry.
RESULTS: The I/M ratio was significantly reduced in eNOS-transfected arteries compared with arteries transfected with empty plasmids and saline-treated controls. Compared to transplanted control arteries, eNOS-transfected arteries demonstrated significantly reduced T-cell infiltration into the intima and significantly reduced macrophage infiltration into the media. Cell surface expression of VCAM-1 and ICAM-1 were both reduced in eNOS-transfected arteries.
CONCLUSIONS: ENOS gene delivery can suppress neointimal lesion formation and T-lymphocyte and macrophage infiltration in transplanted arteries, associated with a reduction in relevant adhesion molecule expression. Thus, gene therapy with eNOS may not only reduce ischemia-reperfusion injury but may also ameliorate transplant arteriopathy in transplanted hearts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11077218     DOI: 10.1016/s1053-2498(00)00200-x

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

1.  Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis.

Authors:  Luis A Brito; Saradha Chandrasekhar; Steven R Little; Mansoor M Amiji
Journal:  Biomed Eng Online       Date:  2010-09-27       Impact factor: 2.819

Review 2.  Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation.

Authors:  Amandeep Dhaliwal; Vinay Thohan
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

Review 3.  Nanoparticulate carriers for the treatment of coronary restenosis.

Authors:  Luis Brito; Mansoor Amiji
Journal:  Int J Nanomedicine       Date:  2007

Review 4.  Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis.

Authors:  Boško Skorić; Maja Čikeš; Jana Ljubas Maček; Željko Baričević; Ivan Škorak; Hrvoje Gašparović; Bojan Biočina; Davor Miličić
Journal:  Croat Med J       Date:  2014-12       Impact factor: 1.351

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.